Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $13.11

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have earned an average rating of “Hold” from the sixteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $13.1111.

NEO has been the subject of several research analyst reports. BTIG Research reiterated a “neutral” rating on shares of NeoGenomics in a research note on Wednesday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a report on Tuesday, November 11th. William Blair reaffirmed a “market perform” rating on shares of NeoGenomics in a research report on Tuesday, July 29th. Piper Sandler set a $11.00 target price on shares of NeoGenomics and gave the company an “overweight” rating in a research note on Monday, August 4th. Finally, Morgan Stanley set a $8.00 target price on NeoGenomics and gave the stock an “equal weight” rating in a research report on Wednesday, July 30th.

NeoGenomics Price Performance

NASDAQ NEO opened at $10.22 on Friday. The stock has a 50-day simple moving average of $9.29 and a 200 day simple moving average of $7.86. NeoGenomics has a twelve month low of $4.72 and a twelve month high of $19.11. The stock has a market capitalization of $1.32 billion, a PE ratio of -11.61 and a beta of 1.67. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.58 and a current ratio of 3.91.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The company had revenue of $187.80 million for the quarter, compared to the consensus estimate of $183.85 million. During the same period in the previous year, the business posted $0.05 EPS. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Research analysts anticipate that NeoGenomics will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Teacher Retirement System of Texas acquired a new stake in NeoGenomics during the first quarter worth $178,000. CWM LLC raised its stake in shares of NeoGenomics by 42.6% in the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock valued at $60,000 after buying an additional 1,883 shares in the last quarter. Bailard Inc. bought a new position in shares of NeoGenomics during the 1st quarter worth about $183,000. Jennison Associates LLC boosted its position in shares of NeoGenomics by 0.8% during the 1st quarter. Jennison Associates LLC now owns 1,527,267 shares of the medical research company’s stock valued at $14,494,000 after acquiring an additional 12,511 shares in the last quarter. Finally, Guidance Capital Inc. boosted its position in shares of NeoGenomics by 27.7% during the 1st quarter. Guidance Capital Inc. now owns 40,910 shares of the medical research company’s stock valued at $388,000 after acquiring an additional 8,880 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.